Showing results (791-800 of 1,193) with videos related to
Sort By:
Pageof 120
Pharmaceutical Statistics|April 28, 2018
BOIN-ET: Bayesian optimal interval design for dose finding based on both efficacy and toxicity outcomesKentaro Takeda, Masataka Taguri, Satoshi MoritaPharmaceutical Statistics|July 21, 2018
Robust Bayesian nonlinear mixed-effects modeling of time to positivity in tuberculosis trialsDivan Aristo Burger, Robert Schall, Ding-Geng ChenPharmaceutical Statistics|July 10, 2018
Design and analysis of a 3-arm noninferiority trial with a prespecified margin for the hazard ratioEisuke Hida, Toshiro TangoPharmaceutical Statistics|July 31, 2018
Weighted log-rank test for time-to-event data in immunotherapy trials with random delayed treatment effect and cure rateShufang Liu, Chenghao Chu, Alan RongPharmaceutical Statistics|August 2, 2018
Propensity score matched augmented controls in randomized clinical trials: A case studyJunjing Lin, Margaret Gamalo-Siebers, Ram TiwariPharmaceutical Statistics|August 2, 2018
Uniformly most powerful Bayesian interval design for phase I dose-finding trialsRuitao Lin, Guosheng YinPharmaceutical Statistics|August 17, 2018
Subgroup-specific dose finding in phase I clinical trials based on time to toxicity allowing adaptive subgroup combinationAndrew G Chapple, Peter F ThallPharmaceutical Statistics|August 17, 2018
Single arm two-stage studies: Improved designs for molecularly targeted agentsP Dutton, J HolmesPharmaceutical Statistics|February 9, 2010
Adapting by calibration the sample size of a phase III trial on the basis of phase II dataDaniele De MartiniPharmaceutical Statistics|February 11, 2010
The correlation structure of longitudinal measurements of vision in patients with macular degenerationTomasz Burzykowski, M BuysePageof 120